Related Experiment Video
Updated: Jul 19, 2026
16:24
Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
Published on: February 21, 2014
Melatonin and estrogen in breast cyst fluids
James B Burch1, Margie Walling, Adam Rush
1Cancer Prevention and Control Program, Center for Colon Cancer Research, WJB Dorn Veterans Affairs Medical Center, Department of Epidemiology and Biostatistics, University of South Carolina, Columbia, SC 29208, USA. burch@gwm.sc.edu
Breast Cancer Research and Treatment
|October 25, 2006
Summary
Women with gross cystic breast disease (GCBD) and specific cyst fluid compositions, like higher melatonin and estrogen, face increased breast cancer risk. Monitoring breast cyst fluid may identify high-risk individuals.
Area of Science:
- Biochemistry
- Oncology
- Endocrinology
Background:
- Gross cystic breast disease (GCBD) is linked to elevated breast cancer risk, but underlying mechanisms are unclear.
- Breast cyst fluid (BCF) composition may hold clues to this increased risk.
- Understanding BCF's biochemical properties is crucial for risk stratification in GCBD patients.
Purpose of the Study:
- To investigate the relationship between GCBD characteristics, breast cancer risk factors, and BCF biochemical composition.
- To analyze BCF components like melatonin, estrogen, DHEA-S, EGF, TGF-B, sodium, and potassium.
- To assess the impact of BCF on breast cancer cell growth in vitro and correlate findings with BCF Na:K ratios.
Main Methods:
- Quantified 10 biochemical constituents in 142 BCF samples from 93 women with GCBD.
- Grouped patients based on BCF sodium-to-potassium (Na:K) ratios, a marker for breast cancer risk.
- Treated human breast cancer cells (MCF-7) with BCF and measured growth effects.
Main Results:
- Larger, more frequent cysts correlated with higher BCF estrogen, DHEA-S, and lower TGF-B1.
- Type 1 cysts (Na:K ≤ 3) showed elevated BCF melatonin, estrogen, DHEA-S, and EGF, with lower TGF-B2 compared to Type 2 cysts (Na:K > 3).
- BCF generally inhibited cell growth; melatonin predicted inhibition, while estrogen predicted stimulation.
Conclusions:
- BCF biochemical profiles, particularly melatonin and estrogen levels, are associated with GCBD characteristics and breast cancer risk.
- Specific BCF compositions, like those in Type 1 cysts, indicate a higher risk profile.
- Biological monitoring of BCF offers a potential method for identifying GCBD patients at greatest risk for breast cancer.
Related Concept Videos
01:24Disorders of the Female Reproductive System
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
01:22Hormonal Regulation of the Menstrual Cycle
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.